Remibrutinib is a selective Bruton's tyrosine kinase inhibitor used as an active pharmaceutical ingredient. It is an oral, targeted compound approved for chronic spontaneous urticaria and has been investigated in other inflammatory conditions.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Remibrutinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Ticagrelor sulphone
pharmaceutical raw material
(RS)-tegafur
pharmaceutical raw material
(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid--4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexan-1-ol (1/1)
pharmaceutical raw material
Oxytocein (A)
pharmaceutical raw material
The international HS code for Remibrutinib (CAS 1787294-07-8) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide
CUABMPOJOBCXJI-UHFFFAOYSA-N
CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C
Sourcing Remibrutinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.